135 related articles for article (PubMed ID: 36824867)
1. A non-canonical Hippo pathway represses the expression of ΔNp63.
Low-Calle AM; Ghoneima H; Ortega N; Cuibus AM; Katz C; Tong D; Prives C; Prywes R
bioRxiv; 2023 Feb; ():. PubMed ID: 36824867
[TBL] [Abstract][Full Text] [Related]
2. A Non-Canonical Hippo Pathway Represses the Expression of ΔNp63.
Low-Calle AM; Ghoneima H; Ortega N; Cuibus AM; Katz C; Prives C; Prywes R
Mol Cell Biol; 2024 Jan; 44(1):27-42. PubMed ID: 38270135
[TBL] [Abstract][Full Text] [Related]
3. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
4. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
5. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
6. WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy.
Qi S; Zhu Y; Liu X; Li P; Wang Y; Zeng Y; Yu A; Wang Y; Sha Z; Zhong Z; Zhu R; Yuan H; Ye D; Huang S; Ling C; Xu Y; Zhou D; Zhang L; Yu FX
Mol Cell; 2022 May; 82(10):1850-1864.e7. PubMed ID: 35429439
[TBL] [Abstract][Full Text] [Related]
7. Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ.
Yi J; Lu L; Yanger K; Wang W; Sohn BH; Stanger BZ; Zhang M; Martin JF; Ajani JA; Chen J; Lee JS; Song S; Johnson RL
Hepatology; 2016 Nov; 64(5):1757-1772. PubMed ID: 27531557
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
9. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth.
Lin C; Yao E; Chuang PT
Dev Biol; 2015 Jul; 403(1):101-13. PubMed ID: 25912685
[TBL] [Abstract][Full Text] [Related]
10. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
11. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
12. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
13. Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.
Valencia-Sama I; Zhao Y; Lai D; Janse van Rensburg HJ; Hao Y; Yang X
J Biol Chem; 2015 Jul; 290(27):16906-17. PubMed ID: 25995450
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive evaluation of Hippo pathway silencing in sarcomas.
Merritt NM; Fullenkamp CA; Hall SL; Qian Q; Desai C; Thomason J; Lambertz AM; Dupuy AJ; Darbro B; Tanas MR
Oncotarget; 2018 Aug; 9(60):31620-31636. PubMed ID: 30167083
[TBL] [Abstract][Full Text] [Related]
15. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
[TBL] [Abstract][Full Text] [Related]
16. Hippo-Independent Regulation of Yki/Yap/Taz: A Non-canonical View.
Cho YS; Jiang J
Front Cell Dev Biol; 2021; 9():658481. PubMed ID: 33869224
[TBL] [Abstract][Full Text] [Related]
17. MEKK2 and MEKK3 orchestrate multiple signals to regulate Hippo pathway.
Lu J; Hu Z; Deng Y; Wu Q; Wu M; Song H
J Biol Chem; 2021; 296():100400. PubMed ID: 33571521
[TBL] [Abstract][Full Text] [Related]
18. YAP Expression and Activity Are Suppressed by S100A7 via p65/NFκB-mediated Repression of ΔNp63.
Li Y; Kong F; Shao Q; Wang R; Hu E; Liu J; Jin C; He D; Xiao X
Mol Cancer Res; 2017 Dec; 15(12):1752-1763. PubMed ID: 28923839
[TBL] [Abstract][Full Text] [Related]
19. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
20. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer.
Xu Y; Song M; Hong Z; Chen W; Zhang Q; Zhou J; Yang C; He Z; Yu J; Peng X; Zhu Q; Li S; Ji K; Liu M; Zuo Q
J Exp Clin Cancer Res; 2023 Jan; 42(1):10. PubMed ID: 36609396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
